Suchergebnisse - "angiotensin II type1 receptor blockers"

PubPharm (1.026)

1

Effects of the valsartan recall on heart failure patients : A nationwide analysis

enthalten in: Pharmacoepidemiology and drug safety | 2024

von Devine, J. | Tadrous, M. | Hernandez, I. | +5

2

A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan

enthalten in: Journal of chromatographic science | 2024

von Gopireddy, R. | Maruthapillai, A. | Mahapatra, S.

3

NITROSAMINE CONTAMINATION WITHIN CARDIAC MULTIMEDICATION - SARTANS (VALSARTAN), CALCIUM CHANNEL BLOCKERS (AMLODIPINE AND NIFEDIPINE), AND ANTIARRHYTHMICS (PROPAFENONE) AS A SIGNIFICANT FACTOR IN THE DEVELOPMENT AND PROGRESSION OF MULTIPLE KERATINOCYTIC CANCERS : ADVANCEMENT ROTATION FLAP FOR KERATOACANTHOMA OF THE UPPER LIP AND UNDERMINING SURGERY FOR BCC OF THE SHOULDER AS AN OPTIMAL DERMATOSURGICAL APPROACH

enthalten in: Georgian medical news | 2023

von Tchernev, G.

4

Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension

enthalten in: Clinical research in cardiology : official journal of the German Cardiac Society | 2023

von Zhang, Y. | Zhao, X. | Huang, H. | +1

5

NITROSOGENESIS OF SKIN CANCER : THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAROXETINE), SNRIS (VENLAFAXINE) AND METFORMIN: THE MOST PROBABLE EXPLANATION FOR THE RISING SKIN CANCER INCIDENCE

enthalten in: Georgian medical news | 2023

von Tchernev, G.

6

Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil : Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry

enthalten in: Journal of pharmaceutical sciences | 2023

von Monteiro, M. | de Lima, P. | Novotny, T. | +7

7

Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension : A Systematic Review and Meta-Analysis

enthalten in: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension | 2023

von Almarjan, A. | Almarjan, S. | Masoud, A.

ErratumIn: High Blood Press Cardiovasc Prev. 2023 May 31;:. - PMID 37256512

8

Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status : A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study

enthalten in: Journal of the American Heart Association | 2023

von Kario, K. | Rakugi, H. | Yarimizu, D. | +3

9

NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY : NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER

enthalten in: Georgian medical news | 2023

von Tchernev, G. | Kordeva, S.

10

Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism

enthalten in: Water research | 2023

von Li, R. | Liang, C. | Svendsen, S. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[103]